Abstract: Propynylaminoindan (e.g., Rasagiline) transdermal compositions are provided. Aspects of the transdermal compositions include a matrix which includes the propynylaminoindan, a pressure sensitive adhesive that includes an acrylate copolymer and a cationic acrylic copolymer. Also provided are methods of using the transdermal compositions and kits containing the transdermal compositions.

Abstract: Compositions for the transdermal delivery of amphetamine in a flexible, finite form are described. The compositions comprise a polymer matrix that includes amphetamine or a pharmaceutically acceptable salt or prodrug thereof and a backing layer comprising a polyurethane film layer and a polyester film layer, with a polyurethane adhesive disposed therebetween. Related methods also are described.

Abstract: A garment used to provide hydration and elasticity to the skin of the abdomen area is disclosed. The garment comprises a detachable front panel configured to encase and secure to the abdomen area. The front panel comprises an inner layer and an outer layer each having an interior side and an exterior side. The exterior side of the inner layer is contiguous to the interior side of the outer layer. The inner layer comprises a gelatinous material comprising proteins. In one embodiment, the interior side of the inner layer comprises a self-adhesive edge which secures the front panel to the abdomen area. In another embodiment, the garment comprises a back strap which secures the front panel to the abdomen area at a first and second region.

Abstract: A method and apparatus for protecting and treating wounds are provided. A housing is adapted to be adhesively secured over the wound of an injured or infected person. The housing has an opening for access to the wound, and is further provided with inlet and outlet ports for the application of therapeutic materials. There is particularly provided a program for a closed looped system for such wound care. Additionally, the invention provides for a protective and treating cover for the eye, which can be either opaque or translucent. Additionally, a mechanism for accurately depositing eye drops without risking injury to the eye is also provided.

Abstract: The present invention provides a titratable transdermal drug delivery system comprising an effective dose of an antithrombotic agent, such as tirofiban, or a pharmaceutically acceptable salt thereof. The dosage of the drug delivered is proportional to the size of the patch applied and achieves 60-85% platelet inhibition. The system enables and individualized treatment for patients. Also provided are methods for the treatment of various disorders where platelet inhibition is desired.

Abstract: An improved wound care system is set forth. The system includes a wound care device having a first end and a second end. A fastener, adapted to extend to a desired length to selectively attach the device at an anchor, wherein the anchor is provided on a second end of the device is also provided. The fastener is sufficiently sized and formed of a suitable material to prevent the device from moving when secured to the anchor. In an embodiment, medicine is provided in a desired treatment area of the device. The medicine can be inserted via a medicinal delivery device by inserting the medicinal delivery device up to a stop on the medicinal delivery device into the wound care device.

Abstract: A medicated patch is provided which is covered with a liner that enables one to remove the liner unconsciously and readily without losing the initial stickiness of the medicated patch. The external medicated patch includes a backing, an aqueous adhesive drug-containing matrix that is spread substantially entirely over one surface of the backing, and a liner that is larger in size than the surface of the drug-containing matrix to which the liner is attached. The liner larger in size than the surface of the drug-containing matrix to which the liner is attached includes an unattached area that extends from the surface of the drug-containing matrix, or an unattached slack portion that projects upward from the surface of the drug-containing matrix at a position on the surface of the drug-containing matrix.

Abstract: A transdermal delivery kit that enhances the efficacy of a topical drug includes at least one drug dispensing device, a lipophilic base, a hydrophilic base, a lipid-soluble active ingredient, a water-soluble active ingredient, a first container for mixing the lipophilic base with the lipid-soluble active ingredient to form a first compound, a second container for mixing the hydrophilic base with the water-soluble active ingredient to form a second compound, a mixing member, and instructions for compounding the lipophilic base with the lipid-soluble active ingredient to form the first compound, compounding the hydrophilic base with the water-soluble active ingredient to form the second compound, and mixing the first compound and the second compound to form a transdermal pharmaceutical delivery system capable of delivering a drug to the dermal layer of the skin.

Abstract: A method of handling an adhesive laminate, wherein the adhesive laminate is provided releasably adhered to a first web, comprising a plurality of cut or punched sections and wherein adjacent sections of the adhesive laminate remain joined to one another in the longitudinal direction of the web through one or more tie points. A first supporting structure and a second supporting structure adjacent to the first supporting structure are provided. The first web is led over the first supporting structure. A second web is provided and led over the second supporting structure, wherein the second web is oriented such that the release surface of the second web faces the first supporting structure.

Abstract: The present invention provides a patch preparation that has an extremely low moisture permeability, has a sufficient ODT effect, is excellent in drug releasability, and has a preferred handleability. The patch preparation of the present invention includes a support; and a pressure-sensitive adhesive layer containing an adherent polymer and a drug on one surface of the support, wherein: the support has a polyester base layer, an inorganic oxide layer, and a polyester nonwoven fabric layer in the stated order; the polyester base layer has a thickness of 1.0 ?m to 16 ?m; and the pressure-sensitive adhesive layer is laminated on the polyester base layer.

Abstract: The invention provides wound dressings comprising an absorbent (porous) hydrogel composition comprising a foam portion which comprises a flexible plasticized hydrophilic polymer matrix having an internal cellular structure, and a continuous portion which comprises a flexible plasticized hydrophilic polymer matrix having relatively continuous internal structure. The continuous portion of the hydrogel composition includes apertures providing fluid flow communication through the continuous portion between an external surface of the continuous portion and the foam portion whereby the foam portion can take up external water or other fluid into the cellular structure through the apertures of the continuous portion. The continuous portion of the hydrogel composition may be tacky to the skin, allowing its use as a bioadhesive.

Abstract: A wound therapy device and a kit for same with a housing material, a gasket disposed around at least a portion of the housing material, a non-woven absorption material, and a port. The gasket is sized and configured such that at least a first portion of the gasket will be adhered to a second portion of the gasket upon a folding of the housing material. A method of using a wound therapy device.

Abstract: An external patch containing diclofenac hydroxyethylpyrrolidine prepared by laminating an adhesive layer on a backing, wherein said adhesive layer is characterized by comprising 5-50% by weight of styrene•isoprene•styrene block copolymer, 20-50% by weight of a tackifier resin, 5-70% by weight of a softening agent, and 0.5-20% by weight of one or more solubilizers selected from N-methyl-2-pyrrolidone, propylene glycol and dimethyl sulfoxide as essential ingredients, and 0.5-20% by weight of diclofenac hydroxyethylpyrrolidine as an active ingredient. The patch has excellent transdermal absorption, less skin-irritation and excellent stability of the drug.

Abstract: The present invention relates to a donepezil transdermal patch comprising a backing layer and a pressure sensitive adhesive matrix layer, wherein the pressure sensitive adhesive matrix layer comprises donepezil free base and an acrylic pressure sensitive adhesive agent selected from the group consisting of a copolymer of 2-ethylhexyl acrylate and vinyl acetate and a copolymer of 2-ethylhexyl acrylate, vinyl acetate, and hydroxyl-containing monomers, and wherein 2-ethylhexyl acrylate is present in an amount of about 65% to about 75%, vinyl acetate is present in an amount of about 25% to about 35%, and the hydroxyl-containing monomers are in an amount of about 0% to about 10%, based on the total weight of the copolymer.

Abstract: The invention relates to a test unit for wound drainage coverings comprising: a base body with at least one cavity; at least one supply line that runs through the base body and which connects an outer side of the base body to the cavity; a surface of the base body that is embodied as a support surface for supporting wound coverings and the wound drainage coverings thereof and several channels that run through the base body, the channels connecting the cavities to the support surface. Low pressure can be produced in the cavity and the channels when the support surface is covered in an air-tight manner. As a result, wound drainage applications are tested in different ways using simple and economical means.

Abstract: A transdermal permeant delivery system for delivery of at least one permeant composition into a tissue membrane of a subject including a disposable substrate having at least a portion of a bottom surface of a first release liner connected to an upper surface of the substrate and a patch having a backing layer and a reservoir that is selectively removable from the top surface of the first release liner. In a connected position, a first portion of the backing layer of the patch is releaseably mounted to a top surface of the first release liner in spaced registration with a poration area of the substrate.

Abstract: A portable system for subatmospheric pressure therapy in connection with healing a surgical wound, includes a wound dressing dimensioned for positioning relative to a wound bed of a subject, a portable subatmospheric pressure mechanism dimensioned to be carried or worn by the subject and a container for collecting exudates from the wound bed removed under the subatmospheric pressure supplied by the subatmospheric pressure mechanism. The portable subatmospheric pressure mechanism includes a housing, a subatmospheric pressure source disposed within the housing and in fluid communication with the wound dressing to supply subatmospheric pressure to the wound dressing and a power source mounted to or within the housing for supplying power to actuate the subatmospheric pressure source.

Abstract: A silicone adhesive composition including an ionic silicone and useful for healthcare applications such as wound care and drug delivery.

Abstract: The transdermal patch contains a base layer, a textured pharmaceutical layer, and a detachable layer, sequentially stacked from top to bottom. The textured pharmaceutical layer contains pressure-sensitive adhesive and medicament, and is configured with at least an embossed pattern for contacting with the skin. After the detachable layer is peeled off from the textured pharmaceutical layer and the latter is attached to the skin, the transfer performance of the contained medicament is significantly enhanced by the embossed pattern's increased area of release to the medicament.

Abstract: A manually operable pump for the effective removal of fluids to include blood, blood clots, fluid, and air from a body cavity of a subject is provided. The manually operable pump is adapted to be connect to a range of fluid conduits and is equipped with one-way valves that effectively permit flow of fluid through the pump in only one direction. The sensitivity of the one-way valves is such that when properly positioned, fluid can flow through the valves and out of the pump without manual compression of the pump and with the aid of gravity power alone.

Abstract: The invention relates to pharmaceutical formulations, in particular to transdermal therapeutic systems, which are characterized in that little or no active ingredient crystallizes out at the interface between the removable protective film (release liner) and the active-ingredient-containing matrix.

Abstract: Wearable patches comprising multiple separable adhesive layers. One or more of the layers can comprise electronics, mechanical components, gauze, medicine and/or other types of hardware suitable for the intended use of the patch. In use, a first layer of the patch is adhered to a user. When it is time to change layers, the patch is removed from the user, the first layer is removed from the patch to expose a second adhesive layer, and the second layer is applied to the user. The process may be repeated until the remaining layers of the patch have been used.

Abstract: Provided is a fentanyl transdermal patch comprising an acrylic-rubber hybrid as a drug-adhesive layer. The fentanyl transdermal patch can maintain constant fentanyl skin permeability for three days by maintaining close contact with the skin such that desorption, release by moisture and sweat, and skin stimulation are all improved.

Abstract: An improved Transdermal Delivery System (TDS) comprising a backing layer inert to the components of the matrix, a self-adhesive matrix containing rotigotine and a protective foil or sheet to be removed prior to use, characterized in that the self-adhesive matrix consists of a solid or semi-solid semi-permeable polymer (1) wherein rotigotine in its free base form has been incorporated, (2) which is saturated with rotigotine and contains said rotigotine as a multitude of microreservoirs within the matrix, (3) which is highly permeable for the free base of rotigotine, (4) which is impermeable for the protonated form of rotigotine, (5) wherein the maximum diameter of the microreservoirs is less than the thickness of the matrix. is provided. Said TDS provides for enhanced flux of rotigotine across the TDS/skin interface.

Abstract: A suction device according to the present invention has: an outer tube connected to a fluid supply unit on a base-end side thereof and including an opening edge section; and a suction tube provided in the outer tube and connected to a negative pressure generating unit on a base-end side thereof, the suction tube including an opening edge section, wherein an annular fluid supply passage is formed between an inner peripheral surface of the outer tube and an outer peripheral surface of the suction tube, and the opening edge section of the suction tube is placed inside the opening edge section of the outer tube toward the base-end side thereof.

Abstract: The present invention relates to a container for anal irrigation. In particular it relates to a rigid container which is easy to operate and which easily is transformed from a storage configuration to a ready-to-use configuration. In one aspect the invention relates to a container for an anal irrigation system. The anal irrigation system comprises an anal probe; a reservoir for holding an irrigation liquid (e.g. water); a pump mechanism for pumping a fluid (e.g. air) into the reservoir; and a liquid tube connecting the reservoir with the anal probe. The container comprises an outer chamber wall, defining at least partly the outer dimensions of the container and an inner chamber wall arranged within the outer chamber wall, said outer chamber wall and inner chamber wall defining the reservoir. This provides a reservoir having a small surface area when filled with irrigation liquid. Thus only a low pressure is necessary to evacuate the irrigation liquid from the reservoir and out through the anal probe.

Abstract: The invention is concerned with a transdermal therapeutic system (TTS) comprising buprenorphine and a method of manufacturing such a TTS. The transdermal therapeutic system is used for the transdermal administration of buprenorphine and analogues thereof. In particular, the invention relates to the use of a transdermal therapeutic system (TTS) for analgesic purposes. The TTS according to the invention comprises a transdermal drug delivery composition comprising buprenorphine and an adhesive component, which is a mixture of a crosslinked and a non-crosslinked acrylic polymer and a penetration enhancer comprising a keto acid.

Abstract: The invention relates to a liquid-permeable primary dressing in the form of a supple thermoplastic section of material (1.4), comprising: a first smooth surface (4); a second surface (5) facing away from the smooth surface (4); and a plurality of three-dimensional perforations, whose walls extend from the first smooth surface (4) and end in an overhang with a free edge, thus making the second surface (5) rough to the touch. At least one of the free edges has an angled section that is approximately perpendicular to a perforation axis. In a preferred embodiment, the periphery (13) of the material section is smooth on both sides, i.e. on both the first and second surfaces (4; 5), the periphery (13) of the surface (5) that was at first rough being thermally smoothed.

Abstract: The present invention provides a transdermal delivery system, which comprises a drug-containing matrix layer comprising: galantamine or its pharmaceutically acceptable salt as an active ingredient; and a styrene-butadiene-styrene copolymer or a styrene-isoprene-styrene copolymer as an adhesive.

Abstract: Disclosed are bupivacaine transdermal delivery systems, and related methods.

Abstract: A blend of at least two polymers in combination with a drug provides a pressure-sensitive adhesive composition for a transdermal drug delivery system in which the drug is delivered from the pressure-sensitive adhesive composition and through dermis when the pressure-sensitive adhesive composition is in contact with human skin.

Abstract: The invention provides a patch and a patch preparation having an adhesive layer with a high adhesive force, wherein the hydrophobic adhesive layer does not bloom even when an organic fluid component having high polarity is contained therein. The patch contains a support and an adhesive layer on at least one surface of the support, wherein the adhesive layer contains a synthetic rubber having a viscosity average molecular weight of 500,000-1,600,000, an organic fluid component having high polarity, a tackifier, and magnesium aluminometasilicate. In the patch preparation, the above-mentioned adhesive layer further contains a drug.

Abstract: In various embodiments, therapeutic tapes are provided. The therapeutic tapes can include a repeating pattern resembling a human fingerprint. The repeating pattern can provide improved therapeutic benefits when applied to a patient's skin.

Abstract: A dermal drug delivery system is provided which comprises at least two components, for example, a sheet of a solid and flexible material, and a vehicle liquid comprising a solvent and optionally other ingredients. A drug, which can be unstable in said solvent but needs the solvent for being delivered into the skin, can be impregnated in the sheet. Other ingredients, such as agents for fastening the drug on the sheet can also be impregnated in the sheet. These two components may be stored separately and joined either shortly before or at the time of application. To use the system, the vehicle liquid may be applied either on the target skin area or on the sheet, and the sheet may then be applied on the target skin area so that the vehicle liquid is positioned between the sheet and the skin and brought into contact with the ingredients impregnated in the sheet.

Abstract: The present invention relates to a patch containing the active ingredient rotigotine for the transdermal delivery of the active pharmaceutical agent rotigotine, comprising a backing layer (1), a matrix layer (2) containing the active ingredient, and a removable protective sheet (4) which is intended for removal before the patch is applied to the skin, characterized in that disposed with areal coverage between the matrix layer (2) and the removable protective sheet (4) is an additional interlayer (3).

Abstract: Devices for administration of one or more active agents to the skin or mucosa of a host are formed in the nature of a double-disk patch. One outer layer functions as the primary adhesive layer for adhering the patch to the host. The other inner layer contains at least one active agent to be administered to the host. The inner layer is bonded to the outer layer through an opening provided in an interposed active agent impermeable release layer. The release layer separates a circumferential portion of the active agent containing inner layer from the outer adhesive layer to inhibit migration of the active agent therebetween.

Abstract: Disclosed is a percutaneous absorption preparation for treatment of dementia that comprises rivastigmine or its pharmaceutically acceptable salt as an active ingredient, a styrene-isoprene-styrene block copolymer, a tackifier resin, and a plasticizer, which preparation contains a small amount of rivastigmine but allows a sufficient amount of the active ingredient penetrated into the skin to achieve an effective treatment of dementia.

Abstract: The present invention relates to a transdermal therapeutic system for administering an active substance through the skin, comprising: a) a cover layer, b) a reservoir present on the cover layer, comprising a polymer matrix comprising the active substance, c) an adhesive layer present on the reservoir comprising a contact adhesive, and d) a removable layer present on the adhesive layer, the active substance being rivastigmine, a physiologically compatible salt, hydrate, solvate or derivative thereof, characterized in that the polymer matrix of the reservoir comprises neither hydroxyl groups nor carboxyl groups.

Abstract: Hydrogel compositions are provided (a) that have a continuous hydrophobic phase and a discontinuous hydrophilic phase, (b) that have a discontinuous hydrophilic phase and a continuous hydrophilic phase, or (c) that are entirely composed of a continuous hydrophilic phase. The hydrophobic phase, if present, is composed of a hydrophobic polymer, particularly a hydrophobic pressure-sensitive adhesive (PSA), a plasticizing elastomer, a tackifying resin, and an optional antioxidant. The discontinuous hydrophilic phase, if present, is composed of a crosslinked hydrophilic polymer, particularly a crosslinked cellulosic polymer such as crosslinked sodium carboxymethylcellulose. For those hydrogel compositions containing a continuous hydrophilic phase, the components of the phase include a cellulose ester composition or an acrylate polymer or copolymer, and a blend of a hydrophilic polymer and a complementary oligomer capable of hydrogen bonding thereto.

Abstract: Disclosed is a patch which is a formulation including deposited clonidine crystals and provides stable transdermal absorbability even after storage at varying temperatures. The patch disclosed includes a backing and a medicated layer integrally superposed on one surface of the backing. The medicated layer contains: 5 to 30% by weight of clonidine including clonidine in a crystallized state; 25 to 90% by weight of a macromolecular base (A) having a viscosity-average molecular weight of 800,000 or larger; and 5 to 60% by weight of a liquid additive capable of dissolving the clonidine. The weight ratio of the liquid additive to the macromolecular base (A) [the liquid additive/the macromolecular base (A)] is 0.1 to 2.0.

Abstract: A portable device (2) to generate a vacuum for the medical treatment of wounds on the bodies of humans or animals has a vacuum-producing suction pump (90) in a first housing part (4) of the device and a vessel (10) for receiving body liquids. Vacuum is applied for vacuum communication between the suction pump (90), the vessel (10) and a suction tube (82) leading to the body. A pressure sensor (94) measures the pressure in a tube section (88) and a programmable electronic control unit (100) controls the suction pump (90) in dependence on pressure values measured by the pressure sensor (94). The electronic control unit (100) deactivates the suction pump (90) if a rate of change in pressure (?p/?t) detected by the pressure sensor (94) exceeds a defined threshold value toward decreasing vacuum.

Abstract: Described generally herein are tissue therapy devices, which may comprise a sealant layer and a suction apparatus. The sealant layer functions so as to create a sealed enclosure between it and the surface of a patient by forming, preferably, an airtight seal around an area of tissue that requires negative pressure therapy. The tissue therapy device may comprise a suction apparatus. The suction apparatus is typically in fluid communication with the sealant layer and functions so as to reduce the amount of pressure present underneath the sealant layer. The reduced pressure is self-created by the suction apparatus. Together the sealant layer and the suction apparatus preferably create a closed reduced pressure therapy system. Preferably, the pressure under the sealant layer is reduced by expanding the volume of the enclosure space and thereby decreasing the density of the air molecules under the sealant layer.

Abstract: Dressings, systems, and methods are disclosed in some embodiments that involve treating a tissue site with reduced pressure wherein the dressing includes a dressing reduced-pressure indicator that allows one to ascertain that the reduced pressure applied at the dressing is greater than a threshold reduced pressure. The dressing reduced-pressure indicator may include a moving member that is adapted to move under reduced pressure and a visual indicator associated with the moving member. Another embodiment uses an electro-mechanical indicator to provide a powered visual alert or audible alert or another output signal. Other dressings, systems, and methods are disclosed.

Abstract: The invention provides an adhesive sheet for adhesion to the skin, as well as a transdermal absorption preparation containing the adhesive sheet and a drug or a pharmaceutically acceptable salt thereof in the adhesive layer of the adhesive sheet. The adhesive sheet comprises a support and an adhesive layer formed on the support, wherein the adhesive layer contains at least a thermoplastic elastomer, and more than 300 parts by weight of liquid paraffin per 100 parts by weight of the elastomer, and wherein the adhesive layer contains not more than 10 wt % of a tackifier.

Abstract: A transdermal patch for the treatment of Alzheimer's disease includes: a backing, a rivastigmine-containing layer, a pressure-sensitive adhesive layer, and a release liner. In the transdermal patch, the rivastigmine-containing layer contains rivastigmine and an alkyl (meth)acrylate resin, the pressure-sensitive adhesive layer is composed of an acrylic pressure-sensitive adhesive containing a (meth)acrylic acid ester having a hydroxy group, and neither the rivastigmine-containing layer nor the pressure-sensitive adhesive layer contains an anti-oxidizing agent.

Abstract: The invention relates to a UV stable transdermal therapeutic system (TTS) consisting of a back layer, at least one matrix containing an active substance and optionally, a withdrawal film and an UV-radiation absorber. An adhesive layer containing said UV-radiation absorber is arranged between the back layer and the matrix containing an active substance which is distant as much as possible from a surface, a separation layer is arranged between the adhesive layer containing said UV-radiation absorber and the matrix containing an active substance, which is as remote as possible from the surface which is impermeable to the active substance and UV-radiation absorber. The inventive transdermal therapeutic system exhibits a high stability and is devoid of inconveniences of existing TTS containing a light-sensitive substance.

Abstract: The purpose of the invention is to produce an imidafenacin-containing percutaneously absorbed preparation, wherein the drug not only is not allowed to crystallize but also has adequate skin penetration. The imidafenacin-containing percutaneously absorbed preparation comprises isostearic acid and a fatty acid ester, which function as crystallization-preventing agents.

Abstract: Apparatus and methods are provided including a patch assembly (20) configured to deliver a substance through a subject's skin. A frame (26) surrounds at least in part an open portion of the patch assembly, such that a region of the skin is exposed through the open portion when the frame is placed on the skin. A substance support area (28) is foldably coupled to the frame at a foldable joint (27). A substance delivery area (23) is adapted to be placed in contact with at least a portion of the region of skin, by the substance support area being folded with respect to the frame. A stiffener (29), disposed on the substance support area between the foldable joint and the substance delivery area, is configured to facilitate the placement of the substance delivery area on the portion of the region of skin. Other applications are also described.

Abstract: The invention relates to a pharmaceutical patch for transdermal administration of the pharmacologically active ingredient (1r,4r)-6?-fluro-N,N-dimethyl-4-phenyl-4?,9?-dihydro-3?H-spiro[cyclohexane-1,1?-pyrano[3,4-b]indol]-4-amine or a physiologically acceptable salt thereof, the patch comprising a surface layer, an adhesive layer, and a removable protective layer, wherein the adhesive layer is located between the surface layer and the removable protective layer.

Abstract: Provided is a percutaneous absorption type formulation of a drug such as imidafenacin and silodosin, wherein stable absorption through the skin is realized. The percutaneous absorption type formulation containing a drug such as imidafenacin and silodosin further contains a transdermal absorption promoting agent, and fatty acid ester and/or fatty acid amide that further improve(s) the function of the transdermal absorption promoting agent.